Regulation of EPCs: The Gateway to Blood Vessel Formation
Figure 6
Schematic of potential therapeutic applications for targeting transcription factors in EPCs. EPCs are known to contribute to vasculogenesis in solid tumours as well as being dysfunctional in conditions which increase patients’ susceptibility to ischemic events. (a) For example, in a tumour setting inhibiting transcription factors which are known to enhance EPC function and contribution to vasculogenesis may result in reduced tumour growth by limiting tumour vascularisation. (b) Conversely, in the context of ischemia, targeting transcription factors in EPCs to enhance their vasculogenic potential could contribute to the amelioration of ischemia.
